中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性肝病致骨质疏松症的机制及防治

段志军 郑淼磊 李钰伶 崔东升

引用本文:
Citation:

慢性肝病致骨质疏松症的机制及防治

基金项目: 

国家自然科学基金资助项目(30970886); 

详细信息
  • 中图分类号: R580

Mechanism, prevention and treatment of osteoporosis in chronic liver disease

Research funding: 

 

  • 摘要: 我国慢性肝病(CLD)极为常见,其中一部分并发症和(或)伴发病严重,预后差。近年CLD与钙磷代谢及骨疾病关系的研究已成为国内外关注的热点。CLD可致肝性骨营养不良,而骨质疏松症(OP)又是最常见的肝性骨营养不良类型。因CLD原发病症状体征的存在,及OP缺乏典型临床表现,OP常被忽视。当伴发自发性骨折或低创伤性骨折时,严重影响了患者的生活质量,甚至危及生命。本文就各种CLD和OP的关系,CLD致OP的机制,以及CLD合并OP的防治对策加以综述,对及时有效地纠正CLD发展过程中OP的发生具有重要临床意义。

     

  • [1]Leboime A, Confavreux CB, Mehsen N, et al.Osteoporosis andmortality[J].Joint Bone Spine, 2010, 77 (Suppl 2) :S107-112.
    [2]Kanis JA.Assessment of fracture risk and its application toscreening for postmenopausal osteoporosis:synopsis of aWHO report.WHO Study Group[J].Osteoporosis Int, 1994, 4 (6) :368-381.
    [3]Wariaghli G, Mounach A, Achemlal L, et al.Osteoporosis inchronic liver disease:a case-control study[J].RheumatolInt, 2010, 30 (7) :893-899.
    [4]Dorothy J, Vander J, Edith O, et al.Use of calcaneal ultra-sound and biochemical markers to assess the density andmetabolic state of the bones of adults with hepatic cirrhosis[J].J Natl Med Assoc, 2007, 99 (9) :1024-1029.
    [5]Taveira A, Pereira F, Fernandes M, et al.Longitudinal evalu-ation of hepatic osteodystrophy in children and adolescentswith chronic cholestatic liver disease[J].Braz J Med BioRes, 2010, 43 (11) :1127-1134.
    [6]Jeffrey PL.Identification, diagnosis, and prevention of oste-oporosis[J].The American journal of managed care, 2011, 17:170-176.
    [7]Bernstein C, Leslie W, Leboff M.AGA technical review onosteoporosis in gastrointestinal disease[J].Gastroenterolo-gy, 2003, 124 (3) :795-841.
    [8]Raisz LG.Pathogenesis of osteoporosis:concepts, conflicts, andprospects[J].J Clin Invest, 2005, 115 (12) :3318-3325.
    [9]Goral V, Simsek M, Mete N.Hepatic osteodystrophyand liver cir-rhosis[J].World J Gastroenterol, 2010, 16 (13) :1639-1643.
    [10]Collier J.Bone disorders in chronic liver disease[J].Hepatol-ogy, 2007, 46 (4) :1271-1278.
    [11]Sif O, Osten L, Hans M, et al.Increased rate of bone lossat the femoral neck in patients with chronic liver disease[J].Eur J Gastroenterol Hepatol, 2002, 14 (1) :43-48.
    [12]Schiefke I, Fach A, Wiedmann M, et al.Reduced bonemi-neral density and altered bone turnover markersin patientswith non-cirrhotic chronic hepatitis B or C infection[J].World J Gastroenterol, 2005, 11 (12) :1843-1847.
    [13]Cijevschi C, Mihai C, Drug VL, et al.Osteoporosis in livercirrhosis-overview[J].Rev Med Chir Soc Med Nat Iasi, 2005, 109 (4) :700-704.
    [14]Mounach A, Ouzzif Z, Wariaghli G, et al.Primary biliary cir-rhosis and osteoporosis:a case-control study[J].J BoneMiner Metab, 2008, 26 (4) :379-384.
    [15]George J, Ganesh HK, Acharya S, et al.Bone mineral densityand disorders of mineral metabolism in chronic liver disease[J].World J Gastroenterol, 2009, 15 (28) :3516-3522.
    [16]Guanabens N, Pares A.Management of osteoporosis in liverdisease[J].Clin Res Hepatol Gastroenterol, 2011, 35 (6-7) :438-445.
    [17]Pusl T, Beuers U.Extrahepatic manifestations of cholestaticliver diseases pathogenesis and therapy[J].Clin Rev AllergyImmunol, 2005, 28 (2) :147-157.
    [18]Leslie WD, Bernstein CN, Leboff MS, et al.AGA technialreview on osteoporosis in hepatic disorders[J].Gastroenter-ology, 2003, 125 (3) :941-966.
    [19]Wolfhag en FH, van Buur en HR, Vleggaar FP, et al.Manage-ment of osteoporosis in primary biliary cirrhosis[J].BaillieresBest Pract Res Clin Gast roenterol, 2000, 14 (4) :629-641.
    [20]Guichelaar M, Malinchoc M, Sibonga J, et al.Bone metabolismin advanced cholestatic liver disease:analysis by bone histo-morphometry[J].Hepatology, 2002, 36 (4) :895-903.
    [21]Moreira R, Duarte M, Farias M.Disturbances of calcium-PTH-vitamin D axis in chronic liver disease[J].Arq BrasEndocrinolMetabol, 2004, 48 (4) :443-450.
    [22]邴玉芝, 姚宏昌, 张自新, 等.慢性肝病患者骨营养不良的临床分析[J].实用肝脏病杂志, 2004, 7 (1) :46-47.
    [23]Luxon BA.Bone disorders in chronic liver diseases[J].CurrGastroenterol Rep, 2011, 13 (1) :40-48.
    [24]Albuquerque Taveira A, Fernandes M, Galvao L, et al.Im-pairment of bone mass development in children with chroniccholestatic liver disease[J].ClinEndocrinol (oxf) , 2007, 66 (4) :518-523.
    [25]Capparelli C, Morony S, Warmington K, et al.Sustained an-tiresorptive effects after a single treatment with human re-combinant osteoprotegerin (OPG) :a pharmacodynamic andpharmacokinetic analysis in rats[J].J Bone Miner Res, 2003, 18 (5) :852-858.
    [26]Crawford B, Labio E, Strasser S, et al.Vitamin D replace-ment for cirrhosis-related bone disease[J].GastroenterolHepatol, 2006, 3 (12) :689-699.
    [27]Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santo-laria-Fernandez F, et al.Serum osteoprotegerin and RANKLlevels in chronic alcoholic liver disease[J].Alcohol, 2006, 41 (3) :261-266.
    [28]Pignata S, Daniele B, Galati M, et al.Oestradiol and testos-terone levels in patients with viral cirrhosis and hepatocellularcarcinoma[J].Eur J Gastroenterol Hepatol, 1997, 9 (3) :283-286.
    [29]陈如山, 阎德文, 王建平, 等.慢性乙肝性肝硬化症男性患者血清性激素、钙调节激素和骨转换指标的变化[J].中国骨质疏松杂志, 2002, 8 (3) :230-233.
    [30]Loria I, Albanese C, Giusto M, et al.Bone disorders in pa-tients with chronic liver isease awaiting liver transplantation[J].Transplant Proc, 2010, 42 (4) :1191-1193.
    [31]Crawford BA, Labio ED, Strasser SI, et al.Vitamin D re-placement for cirrhosis-related bone disease[J].Nat ClinPract Gastroenterol Hepatol, 2006, 3 (12) :689-699.
    [32]Leslie W, Bernstein C, Leboff M, et al.AGA technical re-view on osteoporosis in hepatic disorders[J].Gastroenterol-ogy, 2003, 125 (3) :941-966.
    [33]Boone RH, Cheung AM, Girlan LM, et al.Osteoporosis inprimary biliary cirrhosis:a randomized trial of the efficacy andfeasibility of estrogen/progestin[J].Dig Dis Sci, 2006, 51 (6) :1103-1112.
    [34]Ormarsdottis S, Mallmin H, Naessen T, et al.An open, ran-domized, controlled study of transdermal hormone replace-ment therapy on the rate of bone loss in primary billiary cir-rhosis[J].J Intern Med, 2004, 256 (1) :63-69.
    [35]Pereira S, Donohue J, Moniz C, et al.Trandermal hormonalreplacement therapy improves vertebral bone density in pri-mary biliary cirrhosis:results of a 1-year controlled trial[J].Aliment Pharmacol Ther, 2004, 19 (5) :563-570.
    [36]Hay J, Guichelaar M.Evaluation and management of osteopo-rosis in liver disease[J].Clin Liver Dis, 2005, 9 (4) :747-766.
    [37]张小玉, 王雷, 陆重琳, 等.雷洛昔芬治疗慢性肝病并发骨质疏松症患者40例分析[J].实用医学杂志, 2005, 21 (3) :306-307.
    [38]David M Reid, Jean-Pierre Devogelaer, Kenneth Saag, et al.Zoledronic acid and risedronate in the prevention and treatmentof glucocorticoid-induced osteoporosis (HORIZON) :a multi-centre, double-blind, double-dummy, randomised controlledtrial[J].Lancet, 2009, 373 (6971) :1253-1263.
    [39]Crawford B, Kam C, Pavlovic J, et al.Zoledronic acid pre-vents bone loss after liver transplantation:a randomized, double-blind, placebo-controlled trial[J].Ann InternMed, 2006, 144 (4) :239-248.
    [40]Millonig G, Graziadei I, Eichler D, et al.Alendronate in com-bination with calcium and vitamin D prevents bone loss afterorthotropic liver transplantation:a prospective single-centerstudy[J].Liver Tanspl, 2005, 11 (8) :960-966.
    [41]Zein C, Jorgensen R, Clarke B, et al.Alendronate improvesbone mineral density in primary biliary cirrhosis:a randomizedplacebo-controlled trial[J].Hepatology, 2005, 42 (4) :762-771.
    [42]Lewiecki EM.Safety of long-term bisphosphonate therapyfor the management of osteoporosis[J].Drugs, 2011, 71 (6) :791-814.
    [43]Cranney A, Tugwell P, Zytaruk N, et al.Meta-analysis oftherapies for postmenopausal osteoporosis.VI.Meta-anal-ysis of calcitonin for the treatment of postmenopausal osteo-porosis[J].Endocr Rev, 2002, 23 (4) :540-551.
    [44]Camisasca M, Crosignani A, Battezzati P, et al.Parenteralcalcitonin for metabolic bone disease associated with primarybiliary cirrhosis[J].Hepatology, 1994, 20 (3) :633-637.
    [45]Zhang M, Huang F, Tan Y, et al.Effect of sodium fluorideon bone turnover and bone loss of vertebrae and tibia inovariectomized rats[J].Zhonghua Bing Li Xue Za Zhi, 2000, 29 (1) :49-52.
    [46]张超, 朱勇.经皮椎体成形及后突成形在脊柱外科的应用现状[J].实用骨科杂志, 2003, 9 (6) :505-508.
    [47]林伯庚, 陈治卿, 陈鹭玲.降钙素对骨质疏松症治疗的临床观察[J].中国骨质疏松杂志, 2006, 12 (5) :490-491.
    [48]Arase Y, Suzuki F, Suzuki Y, et al.Virus clearance reducesbone fracture in postmenopausal women with osteoporosisand chronic liver disease caused by hepatitis C virus[J].JMed Virol, 2010, 82 (3) :390-395.
    [49]Guichelaar M, Kendall R, Malinchoc M, et al.Bone mineraldensity before and after OLT:long-term follow-up and pre-dictive factors[J].Liver Transpl, 2006, 12 (9) :1390-1402.
  • 加载中
计量
  • 文章访问数:  236
  • HTML全文浏览量:  27
  • PDF下载量:  180
  • 被引次数: 0
出版历程
  • 出版日期:  2012-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回